After more than a year of research and development, Impact
BioMedical, Inc., and its research partner Global Research and
Discovery Group Sciences (GRDG) announce today that its first
Quantum-based compound was successfully synthesized. The compound
synthesized is an adjuvant which enhances a body’s immune response
to a foreign antigen and is being sent to a major University for
testing.
Impact BioMedical, Inc., a wholly owned subsidiary of Document
Security Systems (NYSE American: DSS), and GRDG Sciences initiated
the research project called Quantum in Summer 2020. The purpose of
the project was two-fold: to forge a new frontier by exploring new
methods for developing medicinal protocols that work more
efficiently, thereby encouraging further research and development
across the pharmaceutical industry, while at the same time
mitigating a projected patent cliff crisis.
A New FrontierThe Quantum technology is designed to enhance
existing therapeutics by looking beyond current molecular
enhancement techniques such as molecular substitution,
halogenation, prenylation and other biological enhancement methods
typical of present therapeutic development schema. This marriage of
quantum and molecular mechanics essentially created a classic
example of bionics that theoretically increases the efficacy
against a variety of diseases.
“We’re very proud of this accomplishment,” said Daryl Thompson
Director of Scientific Initiatives at Global Research and Discovery
Group. “We’ve learned that in general, ‘bionics’ are creating
something mechanical that is inspired by nature. In this case, we
created biological molecules that are inspired by mechanical
aspects such as quantum physics. That’s why we use the term
‘bionics.’”
The increase in the quantum molecule’s therapeutic activity is
due to alterations in the intermolecular state, which yields a
molecule with increased reactivity to ligand interactions with
significantly lower degradation rates. In short, the Quantum
molecule will possess both hyper-reactivity as well as
hyper-persistence.
GRDG Chief Scientific Advisor Dr. Roscoe M. Moore, Jr., the
retired United States Assistant Surgeon General and former Epidemic
Intelligence Services (EIS) Officer at the U.S. Centers for Disease
Control said that this step toward quantum molecules could pave the
way for new medical breakthroughs.
“This is the first step toward a shift in how we create the
medicines we need now and the way we will develop the medicines of
the future,” he said. “This really provides a potential answer to
many medical questions that are out there.”
The Patent CliffA Patent Cliff is a phenomenon that occurs when
the patent expires on a product or a group of products that
represent a high percentage of the total market. The abrupt drop in
sales that follows and the subsequent decrease in a company’s
annual revenue impacts that company’s ability to continue research
and development for future patents.
In the pharmaceutical industry, for example, a patent cliff is
noticed when it affects “blockbuster products,” which the industry
defines as a product with sales exceeding $1 billion per year.
According to the World Health Organization, since 2013 about 95
percent of the world’s essential medicines are off-patent, meaning
that generic equivalents are available. This means that the other 5
percent represents patented medicines, whose income is supporting
further pharmaceutical research and development. As that 5 percent
move out of patent and into the marketplace for generic
alternatives, there will be a $100 billion impact on the whole
industry. This $100 billion sudden drop in revenue will certainly
shrink a company’s ability to produce new medicines and therapies,
stunting the growth of the industry.
As the world climbs out of the COVID-19 pandemic, this looming
threat of a patent cliff takes on greater importance.
“This is what makes today’s announcement so important,” said
Frank D. Heuszel, CEO of Impact BioMedical, Inc. “Creating and
utilizing new methods for therapeutic solutions gives the industry
new and fertile ground upon which to focus new research and
development, which is critical for us to continue to create and
maintain a healthier and safer world.”
Through the Quantum research project, Impact BioMedical and GRDG
have taken the first step in creating a new way to make medicine.
Quantum uses advanced methodologies to create a new class of
medicinal chemistry that we hope will be more effective as compared
with natural compounds and existing drugs while maintaining the
safety profile of the original molecules. This new technique works
on a sub-molecular level to increase the efficacy of the molecules.
We believe that Quantum could be used to improve and re-patent a
variety of therapeutically important compounds.
About Impact BioMedical, Inc.Impact BioMedical,
Inc. ("Impact BioMedical") is a wholly owned subsidiary of DSS.
Impact BioMedical strives to leverage its scientific know-how and
intellectual property rights to provide solutions that have been
plaguing the biomedical field for decades. By tapping into the
scientific expertise of GRDG Sciences, LLC, Impact BioMedical
pledges to undertake a concerted effort in the R&D, drug
discovery and development for the prevention, inhibition, and
treatment of neurological, oncological and immuno-related diseases.
For more information on Impact BioMedical visit
http://impbio.com/.
About Document Security Systems, Inc.DSS is a
multinational company operating businesses focused on blockchain
security, direct marketing, healthcare, consumer packaging, real
estate, renewable energy, and securitized digital assets. Its
business model is based on a distribution sharing system in which
shareholders will receive shares in its subsidiaries as DSS
strategically spins them out into IPOs. Its historic business
revolves around counterfeit deterrent and authentication
technologies, smart packaging, and consumer product engagement. DSS
is led by its Chairman, Mr. Fai Chan, a highly successful global
business veteran of more than 40 years specializing in corporate
transformation while managing risk. He has successfully
restructured more than 35 corporations with a combined value of $25
billion.
For more information on DSS visit
http://www.dsssecure.com.
Investor Contact:Dave Gentry, CEORedChip Companies
Inc.407-491-4498Dave@redchip.com
Safe Harbor DisclosureThis press release
contains forward-looking statements that are made pursuant to the
safe harbor provisions within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. Such forward-looking
statements include, but are not limited to, statements related to
the Company's intended use of proceeds and other statements that
are not historical facts. Forward-looking statements are based on
management's current expectations and are subject to risks and
uncertainties that may cause actual results or events to differ
materially from those projected. These risks and uncertainties,
many of which are beyond our control, include: risks relating to
our growth strategy; our ability to obtain, perform under and
maintain financing and strategic agreements and relationships;
risks relating to the results of development activities; our
ability to attract, integrate and retain key personnel; our need
for substantial additional funds; patent and intellectual property
matters; competition; as well as other risks described in our SEC
filings, including, without limitation, our reports on Forms 8-K,
10-K and 10-Q, all of which can be obtained on the SEC website at
www.sec.gov. Readers are cautioned not to place undue reliance on
the forward-looking statements, which speak only as of the date on
which they are made and reflect management's current estimates,
projections, expectations, and beliefs. We expressly disclaim any
obligation or undertaking to release publicly any updates or
revisions to any forward-looking statements contained herein to
reflect any change in our expectations or any changes in events,
conditions, or circumstances on which any such statement is based,
except as required by law.
DSS (AMEX:DSS)
Historical Stock Chart
From Jun 2024 to Jul 2024
DSS (AMEX:DSS)
Historical Stock Chart
From Jul 2023 to Jul 2024